Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Active not recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 6CNS 4NET 2Gastrointestinal 2Dermatologic 1

Conditions

Glioblastoma 405Brain Neoplasms 163Glioma 159Gliosarcoma 128Astrocytoma 115Central Nervous System Neoplasms 110Oligodendroglioma 74Neuroblastoma 44Medulloblastoma 33Ependymoma 26Recurrence 23Neoplasms 19Neoplasm Metastasis 16Diffuse Intrinsic Pontine Glioma 15Choroid Plexus Neoplasms 13Optic Nerve Glioma 11Melanoma 11Spinal Cord Neoplasms 10Rhabdoid Tumor 10Lymphoma 9Familial ependymoma 9Rhabdomyosarcoma 8Osteosarcoma 8Neuroectodermal Tumors, Primitive 8Breast Neoplasms 8Sarcoma, Ewing 6Sarcoma 6Pinealoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Glioma, Subependymal 6

Interventions

3-Iodobenzylguanidine 13lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 4Temozolomide 4Specimen Handling 4anlotinib 3Magnetic Resonance Spectroscopy 3Everolimus 3pegfilgrastim 2olaparib 2cabozantinib 2belzutifan 2Radiotherapy 2Phenoxybenzamine 2Nivolumab 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Biopsy 2Axitinib 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1tipifarnib 1temsirolimus 1talazoparib 1spartalizumab 1pentetreotide 1penpulimab 1pembrolizumab 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Pheochromocytoma × Temozolomide × CNS × Clear all
NCT04394858 2026-05-13

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
46 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05142241 2025-11-18

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
14 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05885386 2023-06-01

A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL

Peking Union Medical College Hospital

Phase 2 Unknown
20 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05858177 2023-05-15

MPPGL

Peking Union Medical College Hospital

Phase 2 Completed
62 enrolled
CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡